Effect Of Sodium-glucose Cotransporter-2 Inhibitors on Contrast-inducedNephropathy After Angiography

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250701066324N1

Enrollment

120

Registered

2025-07-20

Start date

2025-07-06

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced nephropathy. Acute Kidney Injury, unspecified, secondary to contrast media

Interventions

Intervention 1: Intervention group:Patients in the intervention group will be given 10 mg of empagliflozin immediately after angiography and then 10 mg of empagliflozin daily for one week. Interventio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving 150 to 200 cc of contrast material during coronary angiography/angioplasty

Exclusion criteria

Exclusion criteria: No history of taking SGLT2 inhibitors GFR should not be below 45 mL/min/1.73m²

Design outcomes

Primary

Measure	Time frame
Changes in serum creatinine levels. Timepoint: Serum creatinine measurement before angiography, 2 days, and 7 days after starting the drug. Method of measurement: Creatinine measurement of venous blood samples using Hitachi device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaedeh Hassanpour

Islamic Azad University

Maedeh.hassanpour@iau.ir+98 11 3335 0760

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026